Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SUMMIT

SUMMIT

Tirzepatide · HFpEF + obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Tirzepatide
Population
HFpEF + obesity
Official title
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
completed · 2021-04 → 2024-07
Participants
731
Duration
104 weeks
Registry
NCT04847557

Cardiovascular and kidney outcomes

SUMMIT tirzepatide 5–15 mg vs placebo · HFpEF + obesity · n = 731 · 2024 verified

EndpointHR95 % CIEvents, drug vs controlStatus
Cardiovascular death
Adjudicated death from cardiovascular causes (excludes 2 tirzepatide deaths of undetermined cause, which are counted as CV deaths in the composite)
1.580.52–4.838 vs 5verified
All-cause death
Death from any cause
1.250.63–2.4519 vs 15verified
Hospitalisation for heart failure
Adjudicated worsening heart-failure event resulting in hospitalization (first event)
0.440.22–0.8712 vs 26verified
CV death or worsening HF primary
Adjudicated CV death (including undetermined cause) or worsening heart-failure event (hospitalization, IV therapy in urgent care, or intensified oral diuretics)
0.620.41–0.9536 vs 56verified
Verbatim quotes (4)
  • Cardiovascular death · Abstract; Table 2
    adjudicated death from cardiovascular causes occurred in 8 patients (2.2%) and 5 patients (1.4%), respectively (hazard ratio, 1.58; 95% CI, 0.52 to 4.83)
  • All-cause death · Results, Primary End Points; Table 2
    Death from any cause occurred in 19 patients in tirzepatide group and in 15 patients in the placebo group (hazard ratio, 1.25; 95% CI, 0.63 to 2.45)
  • Hospitalisation for heart failure · Table 2
    Adjudicated worsening heart-failure event resulting in hospitalization — no. (%) 12 (3.3) 1.8 26 (7.1) 3.9 0.44 (0.22 to 0.87)
  • CV death or worsening HF · Results, Primary End Points; Table 2; Figure 1
    occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (...hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)

Outcomes in the indication

SUMMIT Tirzepatide · HFpEF + obesity · 104 weeks · n = 731 seed

CV death or worsening HF HR 0.62; KCCQ-CSS +6.9 points

MeasureDrugControlDifference (95 % CI)Status
Cardiovascular death or worsening heart-failure event (time to first event)
week 104
+9.9+15.3+0.6 (+0.4 to +0.9) hazard ratioverified
KCCQ clinical summary score, change from baseline
week 52
+19.5+12.7+6.9 (+3.3 to +10.6) points (0-100)verified
Verbatim quotes (2)
  • Cardiovascular death or worsening heart-failure event (time to first event)
    Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)
  • KCCQ clinical summary score, change from baseline
    the mean (±SD) change in the KCCQ-CSS was 19.5±1.2 in the tirzepatide group as compared with 12.7±1.3 in the placebo group (between-group difference, 6.9; 95% CI, 3.3 to 10.6; P<0.001)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SUMMIT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/summit/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.